Status and phase
Conditions
Treatments
About
This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (All Participants):
Inclusion Criteria for Participants with Mild Hepatic Impairment (Cohort 1):
Inclusion Criteria for Participants with Normal Hepatic Function (Cohort 2):
Exclusion Criteria (All Participants):
Exclusion Criteria for Participants With Mild Hepatic Impairment (Cohort 1):
Exclusion Criteria for Participants With Normal Hepatic Function (Cohort 2):
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Assembly Biosciences
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal